Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stem Cells SpinWAR:SCS 39 EV-to-EBITDA is 20.76 as of Jul. 31, 2026, which is 3% below its 10-year median of 21.35. GuruFocus rates WAR:SCS with a GF Score™ of 39/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 411 Biotechnology companies, Stem Cells Spin ranks worse than 64.23% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Stem Cells Spin's enterprise value is zł20.26 Mil.
Stem Cells Spin's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.98 Mil. Therefore, Stem Cells Spin's EV-to-EBITDA for today is 20.76.
The historical rank and industry rank for Stem Cells Spin's EV-to-EBITDA or its related term are showing as below:
WAR:SCS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7 Med: 21.35 Max: 75.97
Current: 20.76
During the past 13 years, the highest EV-to-EBITDA of Stem Cells Spin was 75.97. The lowest was 6.70. And the median was 21.35.
WAR:SCS's EV-to-EBITDA is ranked worse than 64.23% of 411
companies
in the Biotechnology industry
Industry Median: 12.05
vs WAR:SCS: 20.76
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stem Cells Spin's PE Ratio (TTM) for today is calculated as:
Stem Cells Spin's share price for today is zł0.488.
Stem Cells Spin's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.014.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Stem Cells Spin's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SCS vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Stem Cells Spin's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stem Cells Spin EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stem Cells Spin's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Stem Cells Spin's EV-to-EBITDA falls into.
Stem Cells Spin's current Enterprise Value is zł20.26 Mil.
Stem Cells Spin's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stem Cells Spin (WAR:SCS) has a EV-to-EBITDA of 20.76 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stem Cells Spin. This is near median its historical median of 21.35. Over the past decade, Stem Cells Spin's EV-to-EBITDA has ranged from 6.70 to 75.97. According to the industry distribution chart, Stem Cells Spin ranks #264 out of 411 companies in the Biotechnology industry, placing it in the top 64.2%.
Is Stem Cells Spin's EV-to-EBITDA too high?
Stem Cells Spin's current EV-to-EBITDA of 20.76 is near median its 10-year median of 21.35. Over the past 10 years, this metric has ranged from a low of 6.70 to a high of 75.97. The Biotechnology industry median EV-to-EBITDA is 12.05. Stem Cells Spin's value of 20.76 is 72.3% above this industry median. Based on the distribution chart, Stem Cells Spin ranks #264 out of 411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Stem Cells Spin has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stem Cells Spin ranks #264 out of 411 companies for EV-to-EBITDA. This places Stem Cells Spin in the lower half of its industry. The industry median EV-to-EBITDA is 12.05. Stem Cells Spin's value of 20.76 is 72.3% above this benchmark. Historically, Stem Cells Spin's own EV-to-EBITDA has ranged from 6.70 to 75.97 over the past decade. While the company's 10-year median is 21.35 vs. the industry median of 12.05, Stem Cells Spin has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.05, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stem Cells Spin's current EV-to-EBITDA of 20.76 is 72.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stem Cells Spin. For the Biotechnology industry, the median EV-to-EBITDA is 12.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stem Cells Spin's current EV-to-EBITDA is 20.76, which is near median its own 10-year median of 21.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.49 — trading 388% above its estimated fair value. The current EV-to-EBITDA is 20.76, which is near median its 10-year median of 21.35 and 72.3% above the Biotechnology industry median of 12.05. Stem Cells Spin's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current EV-to-EBITDA is 20.76 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?
Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued.
The current stock price of zł0.49 is trading 388% above its estimated GF Value™ of zł0.10.
GuruFocus considers Stem Cells Spin to be Significantly Overvalued.
Key valuation signals for WAR:SCS:
EV-to-EBITDA: 20.76 (near median its 10-year median of 21.35)
GF Value™: zł0.10 vs. price of zł0.49 (388% above fair value)
Industry Position: 72.3% above the Biotechnology median (#264 of 411)
No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
39GF Score
Get the complete analysis for WAR:SCS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCS has been successfully added to your 
